Home / Biosimilars / News / Stada in-licenses biosimilar filgrastim

Stada in-licenses biosimilar filgrastim Posted 08/11/2013

German generics giant Stada Arzneimittel (Stada) announced on 28 October 2013 that it was strengthening its activities in the biosimilars area by in-licensing a biosimilar filgrastim product from Canada-based Apotex.

The biosimilar in question is Grastofil (filgrastim), which received approval from the European Medicines Agency on 25 July 2013 [1]. The product is a biosimilar version of Amgen’s originator granulocyte colony-stimulating factor (G-CSF) Neupogen. Grastofil is indicated for the treatment of neutropenia (a low number of white blood cells) caused by cancer chemotherapy. Stada expects to commence sales of Grastofil for nearly all EU countries in 2014.

The agreement with Apotex expands Stada’s biosimilars portfolio by adding ‘a high quality biosimilar at very favourable conditions’, according to Dr Michael Mack, Vice President of Biotechnology at Stada. The partners will use Stada’s international sales structures and comprehensive experience in the European market to market Grastofil.

Grastofil will be available in pre-filled syringes with two different active ingredient concentrations for intravenous or subcutaneous injection. ‘The effectiveness, tolerability and quality of Grastofil are comparable to the original product within the approved area of application,’ explains Dr Mack. ‘This was proven in comprehensive, comparative studies with the original product and has now been confirmed with the approval of the European Commission. With Grastofil, we will be able to offer an inexpensive alternative therapy in the future that doctors, patients and even the public healthcare system will benefit from.’

Sales of filgrastim in Europe in 2011 were Euros 841 million, according to IMS Health.

Related article

Stada and Richter to collaborate on biosimilar development

Reference

1.  GaBI Online - Generics and Biosimilars Initiative. Biosimilars applications under review by EMA – 2013 Q3 [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2013 Nov 8]. Available from: www.gabionline.net/Biosimilars/General/Biosimilars-applications-under-review-by-EMA-2013-Q3

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

Copyright – Unless otherwise stated all contents of this website are © 2013 Pro Pharma Communications International. All Rights Reserved.

Source: Stada

Comments (0)

Generics News Research General

more

Biosimilars News Research General

more